New Risk • Apr 01
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Buy Or Sell Opportunity • Mar 31
Now 22% overvalued after recent price rise Over the last 90 days, the stock has risen 5.3% to CHF27.31. The fair value is estimated to be CHF22.41, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Meanwhile, the company became loss making. Annuncio • Mar 18
PolyPeptide Group AG, Annual General Meeting, Apr 08, 2026 PolyPeptide Group AG, Annual General Meeting, Apr 08, 2026, at 16:00 W. Europe Standard Time. Reported Earnings • Mar 14
Full year 2025 earnings released: €0.64 loss per share (vs €0.59 loss in FY 2024) Full year 2025 results: €0.64 loss per share (further deteriorated from €0.59 loss in FY 2024). Revenue: €391.9m (up 16% from FY 2024). Net loss: €21.2m (loss widened 8.2% from FY 2024). Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 9.7% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings. Buy Or Sell Opportunity • Jan 19
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 27% to CHF29.73. The fair value is estimated to be CHF24.51, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 9.7% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 18% in a year. Earnings are forecast to grow by 92% in the next year. Annuncio • Sep 23
PolyPeptide Group AG Achieves Significant Milestone in Malmo Expansion Project PolyPeptide Group AG announced the successful delivery and installation of pre-built modules at its Malmo, Sweden facility. This marks a key milestone in the company's modular expansion project at the site, which aims to double its solid-phase peptide synthesis (SPPS) capacity. The expansion, first announced in January 2025, is a central component of PolyPeptide's mid-term strategy to meet rising global demand for peptide production. The EUR 100 million metabolic program investment was largely funded by a large pharmaceutical partner and will create around 100 permanent new positions. It is anticipated that the expansion will be significantly faster than previous engineering projects due to the modular construction approach. Following installation, the modules will now undergo mechanical completion and automation, followed by qualification and commissioning. Key Project Highlights: Accelerated timeline: The Malmo capacity expansion is on track to be faster than previous engineering expansions due to the modular approach. Strategic partnership: The EUR 100 million investment was largely funded by a largest pharmaceutical player. Modular construction: Pre-built manufacturing modules installed with proprietary manufacturing systems, delivered and installed on-site. Operational continuity: Existing manufacturing operations remain uninterrupted. Advanced technology: Integrated engineering, automation, and process control. Quality assurance: All modules built to meet stringent pharmaceutical GMP standards. The additional capacity will primarily support one of PolyPeptide's large commercial agreements, contributing to its long-term growth initiatives and capital deployment strategy. As communicated in its mid-term outlook, the company expects over the mid-term horizon and on average, capital expenditures of 15-20% of revenue to ensure capacity beyond 2028. Reported Earnings • Aug 14
First half 2025 earnings released: €0.80 loss per share (vs €0.35 loss in 1H 2024) First half 2025 results: €0.80 loss per share (further deteriorated from €0.35 loss in 1H 2024). Revenue: €167.1m (up 24% from 1H 2024). Net loss: €26.5m (loss widened 133% from 1H 2024). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 57% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings. New Risk • Aug 13
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Annuncio • Apr 11
Polypeptide Group Ag Appoints Jo Lecouilliard as Independent Director PolyPeptide Group AG announced the appointment of Jo LeCouilliard as Independent Director. Buy Or Sell Opportunity • Apr 07
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 52% to CHF14.27. The fair value is estimated to be CHF17.84, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.1% over the last 3 years. Meanwhile, the company became loss making. New Risk • Mar 11
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (7.8% average weekly change). Buy Or Sell Opportunity • Jan 23
Now 24% overvalued Over the last 90 days, the stock has fallen 4.9% to CHF27.25. The fair value is estimated to be CHF21.98, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.7% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 18% in a year. Earnings are forecast to grow by 95% in the next year. New Risk • Dec 23
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Buy Or Sell Opportunity • Dec 16
Now 29% overvalued Over the last 90 days, the stock has fallen 8.5% to CHF29.70. The fair value is estimated to be CHF23.11, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.7% over the last 3 years. Meanwhile, the company became loss making. Buy Or Sell Opportunity • Nov 25
Now 21% overvalued Over the last 90 days, the stock has fallen 19% to CHF27.70. The fair value is estimated to be CHF22.88, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.7% over the last 3 years. Meanwhile, the company became loss making. New Risk • Aug 14
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Buy Or Sell Opportunity • Apr 02
Now 23% undervalued Over the last 90 days, the stock has risen 63% to CHF28.55. The fair value is estimated to be CHF36.86, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.0% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 8.8% in a year. Earnings are forecast to grow by 77% in the next year. Reported Earnings • Mar 14
Full year 2023 earnings released: €1.56 loss per share (vs €0.23 profit in FY 2022) Full year 2023 results: €1.56 loss per share (down from €0.23 profit in FY 2022). Revenue: €324.9m (up 16% from FY 2022). Net loss: €51.4m (down €59.2m from profit in FY 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Life Sciences industry in the United Kingdom. Annuncio • Dec 19
PolyPeptide Group AG, Annual General Meeting, Apr 09, 2025 PolyPeptide Group AG, Annual General Meeting, Apr 09, 2025. Reported Earnings • Aug 19
First half 2023 earnings released: €1.04 loss per share (vs €0.31 profit in 1H 2022) First half 2023 results: €1.04 loss per share (down from €0.31 profit in 1H 2022). Revenue: €131.8m (down 1.4% from 1H 2022). Net loss: €34.3m (down 434% from profit in 1H 2022). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Life Sciences industry in the United Kingdom. Board Change • Jul 26
High number of new and inexperienced directors There are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. No experienced directors. No highly experienced directors. Non-Executive Director Erik Schropp is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. 
